Axcella: Rises as FDA clears application for liver disease treatment study

Axcella Health

13/04/2021 14:20

** Biotech co's shares  AXLA.O  rise 8.5% to $4.59 premarket
    ** Co says U.S. FDA clears Investigational New Drug
application for AXA1125, co's treatment candidate for
nonalcoholic steatohepatitis (NASH), a chronic and progressive
liver disease  urn:newsml:reuters.com:*:nBw6w8rlJa
    ** Says FDA clearance allows co to proceed into a midstage
clinical trial
    ** Co expects to begin the trial in Q2 2021, and enroll
about 270 patients at 70 sites globally
    ** NASH is the most severe form of non-alcoholic fatty liver
disease and is estimated to impact up to 40 mln Americans - co
    ** Up to last close, AXLA stock down ~19% this year

 (Reporting by Vishwadha Chander in Bengaluru)
 ((Vishwadha.Chander@thomsonreuters.com;))